Cerus (NASDAQ:CERS – Get Rating) announced its earnings results on Thursday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03, MarketWatch Earnings reports. Cerus had a negative net margin of 41.55% and a negative return on equity of 63.31%. During the same quarter last year, the company earned ($0.10) EPS.
CERS stock traded up $0.48 on Friday, reaching $5.28. 3,167,062 shares of the company were exchanged, compared to its average volume of 1,652,518. Cerus has a 12 month low of $4.38 and a 12 month high of $8.06. The stock’s fifty day moving average price is $5.22 and its 200 day moving average price is $5.93. The firm has a market capitalization of $935.09 million, a PE ratio of -18.86 and a beta of 1.21. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.38 and a quick ratio of 2.04.
CERS has been the topic of a number of research reports. StockNews.com initiated coverage on shares of Cerus in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Zacks Investment Research lowered shares of Cerus from a “buy” rating to a “hold” rating in a research report on Friday, February 25th.
Institutional investors have recently made changes to their positions in the business. Millennium Management LLC increased its holdings in Cerus by 34.7% in the 2nd quarter. Millennium Management LLC now owns 15,007 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 3,867 shares during the period. Royal Bank of Canada boosted its stake in shares of Cerus by 18.3% in the 2nd quarter. Royal Bank of Canada now owns 16,217 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 2,505 shares in the last quarter. LPL Financial LLC boosted its stake in shares of Cerus by 12.3% in the 3rd quarter. LPL Financial LLC now owns 16,401 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 1,800 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Cerus in the 3rd quarter valued at $103,000. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of Cerus by 367.5% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 29,979 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 23,567 shares in the last quarter. 85.56% of the stock is currently owned by hedge funds and other institutional investors.
About Cerus (Get Rating)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
- Get a free copy of the StockNews.com research report on Cerus (CERS)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.